Dynamic expression of hepatic GP73 mRNA and protein and circulating GP73 during hepatocytes malignant transformation

Wang, Sai; Yao, Min; Shen, S J; Zheng, Wenjie; Sun, Jing; Wu, Mengna; Wang, Li; Yao, Dengfu

doi:10.1016/j.hbpd.2020.02.009

Cited by 11 publications

(8 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among them, GOLM1 (also known as GP73 or GOLPH2) is the most anticipated tumor biomarker. A growing number of studies have shown that the abnormal expression of GOLM1 is associated with HCC and may become a new target for the prevention, monitoring and treatment of HCC [4][5][6][7]. In this review, we discuss the recent advances of GOLM1 in HCC and present an overall view of future research.…”

mentioning

confidence: 99%

Recent advances of GOLM1 in hepatocellular carcinoma

Yan

Zhou

et al. 2020

Hepat. Oncol.

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is one of the most common liver malignancies and is a leading cause of cancer-related deaths. Most HCC patients are diagnosed at an advanced stage and current treatments show poor therapeutic efficacy. It is particularly urgent to explore early diagnosis methods and effective treatments of HCC. There are a growing number of studies that show GOLM1 is one of the most promising markers for early diagnosis and prognosis of HCC. It is also involved in immune regulation, activation and degradation of intracellular signaling factors and promotion of epithelial–mesenchymal transition. GOLM1 can promote HCC progression and metastasis. The understanding of the GOLM1 regulation mechanism may provide new ideas for the diagnosis, monitoring and treatment of HCC.

show abstract

mentioning

confidence: 99%

Recent advances of GOLM1 in hepatocellular carcinoma

Yan

Zhou

et al. 2020

Hepat. Oncol.

View full text Add to dashboard Cite

show abstract

“…Obstructions in detecting and analyzing the comprehensive immune microenvironment of each patient in a clinical context mean that there are still obstacles in therapeutic target identification and efficacy monitoring of immunotherapy for HCC. Although we have already identified several biomarkers to predict prognosis and evaluate the efficacy of treatment for HCC, such as alpha-fetoprotein (AFP) [ 25 ], Des-Carboxy Prothrombin (DCP) [ 26 ], osteopontin (OPN) [ 27 ], vascular endothelial growth factor (VEGF) [ 28 ], and Golgi protein 73 (Gp-73) [ 29 , 30 ], representative and credible biomarkers that could precisely reflect the immune modulation of the TME are highly desirable.…”

Section: Discussionmentioning

confidence: 99%

Interleukin-2 inducible T-cell kinase: a potential prognostic biomarker and tumor microenvironment remodeling indicator for hepatocellular carcinoma

Pan

Yang

Wei

et al. 2021

Aging

View full text Add to dashboard Cite

Background: The heterogeneous tumor microenvironment (TME) contributes to poor prognosis of hepatocellular carcinoma (HCC). However, determining the modulation of TME during HCC progression remains a challenge. Methods: Herein, the stromal score and immune score of HCC samples from The Cancer Genome Atlas database were calculated using the ESTIMATE algorithm and differentially expressed genes (DEGs) were obtained. Key DEGs were identified based on a protein-protein interaction network and survival analysis. Immunohistochemistry was carried out using primary samples to evaluate key DEGs expression. The CIBERSORT algorithm was applied to evaluate immune components. Gene Set Enrichment Analysis (GSEA) and correlation analysis were carried out to determine the relationship between key DEGs and tumor-infiltrating immune cells (TICs). Results: The stromal score, immune score and estimate score correlated significantly with 1-year recurrence-free survival of patients with HCC. Interleukin-2 inducible T-cell kinase (ITK) was identified as the most prognostic DEG for patients with HCC. GSEA revealed that genes in the high ITK subgroup were enriched in inflammatory-immunological terms. CIBERSORT analysis identified nine TIC subsets that correlated with ITK expression. Conclusion: We identified ITK as a novel indicator for early post-surgery tumor recurrence and microenvironment remodeling in HCC, providing a potential therapeutic target to treat HCC.

show abstract

“… 19 , 30 – 32 In addition, serum GP73 concentration is positively associated with HCC progression and negatively linked with clinical outcomes. 18 , 33 – 40 A large cohort study consisting of 1690 healthy adults, 337 HBV carriers, and 789 HCC patients revealed that HCC patients have significantly higher serum GP73 levels than healthy people and HBV carriers without noticeable liver disease. 19 Another study examined the relationship between serum GP73 concentration and HCC treatment in 9 patients.…”

Section: Gp73 As a Serum Marker For Hcc Diagnosismentioning

confidence: 99%

Golgi protein 73, hepatocellular carcinoma and other types of cancers

Wang

Wan

2020

Liver Research

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is one of the most common malignant tumors with a low survival rate. The identification of mechanisms underlying the development of HCC helps uncover cellular and molecular targets for the diagnosis, prevention, and treatment of HCC. Golgi protein 73 (GP73) level is upregulated in HCC patients and potentially can be a therapeutic target. Despite many studies devoted to GP73 as a marker for HCC early diagnosis, there is little discussion about the function of GP73 in HCC tumorigenesis. Given the poor response to currently available HCC therapies, a better understanding of the role of GP73 in HCC may provide a new therapeutic target for HCC. The current paper summarizes the role of GP73 as a diagnostic marker as well as its roles in liver carcinogenesis. Its roles in other types of cancer are also discussed.

show abstract

Dynamic expression of hepatic GP73 mRNA and protein and circulating GP73 during hepatocytes malignant transformation

Cited by 11 publications

References 29 publications

Recent advances of GOLM1 in hepatocellular carcinoma

Recent advances of GOLM1 in hepatocellular carcinoma

Interleukin-2 inducible T-cell kinase: a potential prognostic biomarker and tumor microenvironment remodeling indicator for hepatocellular carcinoma

Golgi protein 73, hepatocellular carcinoma and other types of cancers

Contact Info

Product

Resources

About